This study investigates pancreatic cancer. It focuses on reducing acute toxicity after treatment with chemoradiotherapy using oral immunonutrition.
The study evaluates the safety and effectiveness of oral immunonutrition. It looks at how this therapy might help manage treatment-related side effects.
- Who can participate: Adults aged 18 and older with confirmed pancreatic ductal epithelial tumors can participate. Key factors include having a good performance status.
- Study details: Participants will take oral immunonutrition for 6 weeks. A placebo is not used in this study.
- Study timelines: The study will last 4 months.